journal article·2021-03-31Open access

Poly(ethylene glycol)-Mediated Assembly of Vaccine Particles to Improve Stability and Immunogenicity

Guiqiang Zhang, Xiao Fu, Haifeng Sun, Peiyu Zhang, Shumei Zhai, Jingcheng Hao, Jiwei Cui, Ming Hu

ACS Applied Materials & Interfaces· Volume 13· Issue 12

Abstract

We report the one-step assembly of vaccine particles by encapsulating ovalbumin (OVA) and cytosine-phosphate-guanine oligodeoxynucleotides (CpG) into poly(ethylene glycol) (PEG)-mediated zeolitic imidazolate framework-8 nanoparticles (OVA-CpG@ZIF-8 NPs), where PEG improves the stability and dispersity of ZIF-8 NPs and the NPs protect the encapsulated OVA and CpG to circumvent the cold chain issue. Compared with free OVA and OVA-encapsulated ZIF-8 (OVA@ZIF-8) NPs, OVA-CpG@ZIF-8 NPs can enhance antigen uptake, cross-presentation, dendritic cell (DC) maturation, production of specific antibody and cytokines, and CD4 + T and CD8 + T cell activation. More importantly, the vaccine particles retain their bioactivity against enzymatic degradation, elevated temperatures, and long-term storage at ambient temperature. The study highlights the importance of PEG-mediated ZIF-8 NPs as a vaccine delivery system for the promising application of effective and cold chain-independent vaccination against diseases.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: European Union Policy and Governance · Political Influence and Corporate Strategies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Colloid and Interface Chemistry of the Ministry of Education, School of Chemistry and Chemical Engineering, Shandong University, Jinan, Shandong 250100, China

State Key Laboratory of Microbial Technology, Shandong University, Qingdao, Shandong 266237, China

Advanced Medical Research Institute, Shandong University, Jinan, Shandong 250012, China

School of Physics and Electronic Science, East China Normal University, Shanghai 200241, China

Funding

Government of Shandong Province · China Postdoctoral Science Foundation · National Natural Science Foundation of China

References (57)

Show source-provided references
1. 10.1038/nmat377510.1038/nmat3775 ↗
2. 10.1021/acsnano.8b0595010.1021/acsnano.8b05950 ↗
3. 10.1021/nn305466z10.1021/nn305466z ↗
4. 10.1016/j.jconrel.2018.11.00610.1016/j.jconrel.2018.11.006 ↗
5. 10.1021/acs.chemrev.5b0010910.1021/acs.chemrev.5b00109 ↗
6. 10.1021/nn506202910.1021/nn5062029 ↗
7. 10.1021/acsnano.7b0097810.1021/acsnano.7b00978 ↗
8. 10.1038/nm0909-98410.1038/nm0909-984 ↗
9. 10.1586/14760584.2013.81120810.1586/14760584.2013.811208 ↗
10. 10.7150/thno.2169110.7150/thno.21691 ↗
11. 10.1021/acsami.8b1008110.1021/acsami.8b10081 ↗
12. 10.1016/j.biomaterials.2017.09.02910.1016/j.biomaterials.2017.09.029 ↗
13. 10.2217/nnm.14.1610.2217/nnm.14.16 ↗
14. 10.1021/acsnano.7b0805610.1021/acsnano.7b08056 ↗
15. 10.1073/pnas.152486411310.1073/pnas.1524864113 ↗
16. 10.1002/anie.20120615410.1002/anie.201206154 ↗
17. 10.1126/science.109176910.1126/science.1091769 ↗
18. 10.1128/JVI.01553-0810.1128/JVI.01553-08 ↗
19. 10.1016/j.vaccine.2015.08.08510.1016/j.vaccine.2015.08.085 ↗
20. 10.1126/scitranslmed.300049010.1126/scitranslmed.3000490 ↗
21. 10.1038/ncomms1352010.1038/ncomms13520 ↗
22. 10.1021/nn506327610.1021/nn5063276 ↗
23. 10.1021/acs.molpharmaceut.6b0007210.1021/acs.molpharmaceut.6b00072 ↗
24. 10.1016/j.jconrel.2016.05.01210.1016/j.jconrel.2016.05.012 ↗
25. 10.1016/j.vaccine.2010.01.01110.1016/j.vaccine.2010.01.011 ↗
26. 10.1021/jacs.8b0107210.1021/jacs.8b01072 ↗
27. 10.1021/jacs.8b1199610.1021/jacs.8b11996 ↗
28. 10.1021/jacs.8b0358410.1021/jacs.8b03584 ↗
29. 10.1021/jacs.7b1175410.1021/jacs.7b11754 ↗
30. 10.1016/j.colsurfa.2019.02.02510.1016/j.colsurfa.2019.02.025 ↗
31. 10.1246/bcsj.2018036810.1246/bcsj.20180368 ↗
32. 10.1016/j.ccr.2020.21325610.1016/j.ccr.2020.213256 ↗
33. 10.1002/adma.20180514810.1002/adma.201805148 ↗
34. 10.1021/acsami.8b2050410.1021/acsami.8b20504 ↗
35. 10.1021/jacs.8b1030210.1021/jacs.8b10302 ↗
36. 10.1038/ncomms824010.1038/ncomms8240 ↗
37. 10.1002/adma.20160233510.1002/adma.201602335 ↗
38. 10.1002/adfm.20160065010.1002/adfm.201600650 ↗
39. 10.1016/j.biomaterials.2017.01.01710.1016/j.biomaterials.2017.01.017 ↗
40. 10.1016/j.jconrel.2019.02.03510.1016/j.jconrel.2019.02.035 ↗
41. 10.1038/s41467-020-17637-z10.1038/s41467-020-17637-z ↗
42. 10.1039/C6CC09280B10.1039/C6CC09280B ↗
43. 10.1021/acsami.8b0168010.1021/acsami.8b01680 ↗
44. 10.1021/jacs.8b0445710.1021/jacs.8b04457 ↗
45. 10.1080/10610278.2019.161608910.1080/10610278.2019.1616089 ↗
46. 10.1039/D0CC03734F10.1039/D0CC03734F ↗
47. 10.1002/adma.20170440810.1002/adma.201704408 ↗
48. 10.1016/S0092-8674(01)00456-110.1016/S0092-8674(01)00456-1 ↗
49. 10.1038/nm164310.1038/nm1643 ↗
50. 10.1038/nri278010.1038/nri2780 ↗
51. 10.1038/nri325410.1038/nri3254 ↗
52. 10.1146/annurev-immunol-041015-05542010.1146/annurev-immunol-041015-055420 ↗
53. 10.1084/jem.2020067810.1084/jem.20200678 ↗
54. 10.1172/JCI13724410.1172/JCI137244 ↗
55. 10.1073/pnas.120621010910.1073/pnas.1206210109 ↗
56. 10.1016/j.vaccine.2015.05.07110.1016/j.vaccine.2015.05.071 ↗
57. 10.1038/nbt.339810.1038/nbt.3398 ↗